PARIS - Flamel Technologies SA and Bristol-Myers Squibb Co. signed a licensing and commercialization agreement covering Flamel's human insulin product, Basulin. (BioWorld International)

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
Quince’s eDSP on ice after Neat phase III fails in A-T
BioWorld
Quince Therapeutics Inc. is scrapping work with dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) for patients with...